LifeStance Crushes Q2: Revenue Up 26%, Swings to Profit, Raises Guidance, and Authorizes $100M Buyback
LFST has more than doubled off its 52-week low of $3.805.
Summary
LifeStance Health reported Q2 2026 revenue of $435.4M (up 26% YoY), net income of $23.6M (vs. a $3.8M loss last year), and raised full-year guidance. The board also authorized a new $100M share buyback.
Key Events · Earnings and Guidance · LFST
-
Q2 Revenue Surges 26%
Revenue hit $435.4M, driven by 19% visit growth and higher revenue per visit. Clinician base expanded 11% to 8,542.
-
Swings to Profitability
Net income was $23.6M, a dramatic improvement from a $3.8M loss in Q2 2025. Adjusted EBITDA jumped 94% to $66.0M (15.2% margin).
-
Full-Year Guidance Raised
2026 revenue outlook lifted to $1.685B-$1.725B, Center Margin to $570M-$594M, and Adjusted EBITDA to $215M-$235M.
-
New $100M Share Buyback Authorized
Board approved a new $100M repurchase program, replacing the prior $100M program. The company repurchased $97.6M of stock in H1 2026.
Analysis · LFST · Industrial Applications And Services
A standout quarter saw LifeStance swing from a year-ago loss to a $23.6M profit on 26% revenue growth. The company raised full-year guidance across all key metrics and authorized a new $100M share repurchase program, signaling confidence in its cash generation and growth trajectory. This combination of strong execution and shareholder-friendly capital allocation is a clear positive signal, especially against a backdrop of heavy insider selling earlier this year.
At the time of this filing, LFST was trading at $10.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4B. The 52-week trading range was $3.81 to $11.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.